Dose-related Allergic Reactions Decrease Over Time During Peanut Oral Immunotherapy in a Large, Randomized, Double-blind, Placebo-controlled, Phase 2 Study

Andrew Long; Natasha Purington; Sandra Andorf; Katherine O'Laughlin; Shu-Chen Lyu; Sayantani Sindher; Monali Manohar Manohar; Scott Boyd; Robert Tibshirani; Holden Maecker; Kaori Mukai; Mindy Tsai; Manisha Desai; Sharon Chinthrajah; Stephen Galli; Kari Nadeau

doi:10.1016/j.jaci.2019.12.530

Dose-related Allergic Reactions Decrease Over Time During Peanut Oral Immunotherapy in a Large, Randomized, Double-blind, Placebo-controlled, Phase 2 Study

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2019.12.530 ◽

2020 ◽

Vol 145 (2) ◽

pp. AB134

Author(s):

Andrew Long ◽

Natasha Purington ◽

Sandra Andorf ◽

Katherine O'Laughlin ◽

Shu-Chen Lyu ◽

...

Keyword(s):

Oral Immunotherapy ◽

Allergic Reactions ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Over Time

Download Full-text

Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2019.12.384 ◽

2020 ◽

Vol 145 (2) ◽

pp. AB181

Author(s):

Sharon Chinthrajah ◽

Natasha Purington ◽

Sandra Andorf ◽

Andrew Long ◽

Katherine O'Laughlin ◽

...

Keyword(s):

Peanut Allergy ◽

Oral Immunotherapy ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study

The Lancet ◽

10.1016/s0140-6736(19)31793-3 ◽

2019 ◽

Vol 394 (10207) ◽

pp. 1437-1449 ◽

Cited By ~ 40

Author(s):

R Sharon Chinthrajah ◽

Natasha Purington ◽

Sandra Andorf ◽

Andrew Long ◽

Katherine L O'Laughlin ◽

...

Keyword(s):

Peanut Allergy ◽

Oral Immunotherapy ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

Faculty Opinions recommendation of P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725255169.793503497 ◽

2015 ◽

Author(s):

Brendan J Canning

Keyword(s):

Receptor Antagonist ◽

Chronic Cough ◽

Phase 2 ◽

P2x3 Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734506216.793579336 ◽

2020 ◽

Author(s):

Nathalie Gaspar

Keyword(s):

Adult Patients ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Metastatic Osteosarcoma ◽

Phase 2 Study

Download Full-text

Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study

British Journal of Cancer ◽

10.1038/s41416-021-01356-3 ◽

2021 ◽

Author(s):

Ying Cheng ◽

Qiming Wang ◽

Kai Li ◽

Jianhua Shi ◽

Ying Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Phase 2 ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

SAT0110 Efficacy and Safety of Pateclizumab (Anti-Lymphotoxin-Alpha) in Dmard-Ir Patients: Results of a Randomized, Double-Blind, Placebo-Controlled Head-To-Head Phase 2 Study with Adalimumab

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-eular.1836 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A617.2-A618

Author(s):

W. Kennedy ◽

P. Horn ◽

Z. Su ◽

K. Basu ◽

A. Herman ◽

...

Keyword(s):

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Lymphotoxin Alpha

Download Full-text

Faculty Opinions recommendation of Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.733519001.793576228 ◽

2020 ◽

Author(s):

Pedro Machado

Keyword(s):

Ankylosing Spondylitis ◽

Dose Finding ◽

Phase 2 ◽

Proof Of Concept ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study

The Lancet Rheumatology ◽

10.1016/s2665-9913(20)30342-8 ◽

2020 ◽

Author(s):

Ian N Bruce ◽

Alireza Nami ◽

Erik Schwetje ◽

M Edward Pierson ◽

Tomas Rouse ◽

...

Keyword(s):

Lupus Erythematosus ◽

Type I Interferon ◽

Gene Signature ◽

Type I ◽

Phase 2 ◽

Double Blind ◽

High Type ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Interferon Gene

Download Full-text

A multinational, randomized, double-blind, placebo-controlled Phase 2 study to assess safety and efficacy of olesoxime in Type 2 or non-ambulatory Type 3 spinal muscular atrophy

Neuromuscular Disorders ◽

10.1016/s0960-8966(17)30304-8 ◽

2017 ◽

Vol 27 ◽

pp. S29

Author(s):

J. Buchbjerg ◽

E. Bertini ◽

E. Dessaud ◽

E. Mercuri ◽

F. Muntoni ◽

...

Keyword(s):

Spinal Muscular Atrophy ◽

Muscular Atrophy ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Type 3

Download Full-text

Review for "A Twelve‐Week, Randomized, Double‐Blind, Placebo‐Controlled, Four‐Arm Dose‐Finding Phase 2 Study Evaluating Bexagliflozin as a Monotherapy for Adults with Type 2 Diabetes"

10.1111/dom.13928/v2/review2 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Dose Finding ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text